Analysts See $-0.20 EPS for Endologix, Inc. (ELGX)

April 26, 2018 - By reb123z

Endologix, Inc. (NASDAQ:ELGX) LogoInvestors sentiment increased to 1.1 in 2017 Q4. Its up 0.03, from 1.07 in 2017Q3. It increased, as 13 investors sold Endologix, Inc. shares while 26 reduced holdings. 16 funds opened positions while 27 raised stakes. 87.08 million shares or 4.75% more from 83.13 million shares in 2017Q3 were reported.
Brown Mngmt Ltd Company holds 0.57% or 8.78M shares. Bnp Paribas Asset Holdg Sa has 1.68M shares. Palisade Capital Mgmt Limited Liability Company Nj has 0.22% invested in Endologix, Inc. (NASDAQ:ELGX). Ameritas Invest Prns reported 10,000 shares stake. American Gru holds 55,397 shares or 0% of its portfolio. Columbia Wanger Asset Mgmt Llc holds 0.27% in Endologix, Inc. (NASDAQ:ELGX) or 3.39 million shares. Balyasny Asset Management Limited holds 0% of its portfolio in Endologix, Inc. (NASDAQ:ELGX) for 25,900 shares. Tower Research (Trc) holds 0% in Endologix, Inc. (NASDAQ:ELGX) or 3,280 shares. Royal Bancorp Of Canada invested in 1,585 shares or 0% of the stock. Sg Americas Securities Lc accumulated 15,149 shares. Proshare Advsr Ltd Company has invested 0% in Endologix, Inc. (NASDAQ:ELGX). Moreover, Rhenman Asset Mngmt has 0.69% invested in Endologix, Inc. (NASDAQ:ELGX) for 956,002 shares. California Public Employees Retirement System holds 0% or 98,400 shares. Morgan Stanley reported 0% in Endologix, Inc. (NASDAQ:ELGX). Teacher Retirement Systems Of Texas reported 26,894 shares.

Analysts expect Endologix, Inc. (NASDAQ:ELGX) to report $-0.20 EPS on May, 2 after the close.They anticipate $0.02 EPS change or 11.11 % from last quarter’s $-0.18 EPS. After having $-0.08 EPS previously, Endologix, Inc.’s analysts see 150.00 % EPS growth. The stock increased 1.20% or $0.05 during the last trading session, reaching $4.23. About 503,358 shares traded. Endologix, Inc. (NASDAQ:ELGX) has declined 41.08% since April 26, 2017 and is downtrending. It has underperformed by 52.63% the S&P500.

Endologix, Inc. (NASDAQ:ELGX) Ratings Coverage

Among 5 analysts covering Endologix (NASDAQ:ELGX), 1 have Buy rating, 1 Sell and 3 Hold. Therefore 20% are positive. Endologix had 6 analyst reports since November 8, 2017 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus with “Hold” on Thursday, February 22. The stock has “Hold” rating by Stifel Nicolaus on Wednesday, November 8. The rating was maintained by RBC Capital Markets with “Hold” on Wednesday, November 8. On Tuesday, January 2 the stock rating was downgraded by JP Morgan to “Underweight”. BMO Capital Markets maintained the stock with “Hold” rating in Tuesday, December 12 report.

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company has market cap of $355.26 million. It offers minimally-invasive endovascular repair products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. It currently has negative earnings. The firm also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens.

Endologix, Inc. (NASDAQ:ELGX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: